BIOFLOW-III All-comers Orsiro Safety and Performance Registry
Unknown statusNCT01553526
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
Study details
- Official title
- BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III
- Sponsor
- Biotronik AG
- Start date
- 2011-08
- Primary completion
- 2013-03
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Austria, Chile, Denmark, France, Germany, Italy, Latvia, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
- Total sites listed
- 43
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Symptomatic coronary artery disease * Subject has signed informed consent for data release * Subject is geographically stable and willing to participate at all follow-up assessments * Subject is ≥ 18 years Exclusion Criteria: * Subject did not sign informed consent for data release * Pregnancy * Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media * Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained * Currently participating in another study and primary endpoint is not reached yet.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01553526